Recently, the Category 1 innovative drug Fultagliptin Benzoate Tablets (trade name: 信立汀) of Shenzhen Salubris Pharmaceuticals Co., Ltd. is approved by China NMPA. This drug is indicated for improving the blood glucose control for adult patients with type 2 diabetes.

Fultagliptin Benzoate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, can inhibit the activity of DPP-4, and reduce the hydrolysis of incretin hormones by DPP-4, thereby increasing the plasma concentration of active glucagon-like peptide-1 (GLP-1) and glucose dependent insulin-like polypeptide (GIP). It increases the release of insulin in a glucose dependent manner and decreases glucagon to reduce blood glucose. The marketing of this drug provides a new treatment option for adult patients with type 2 diabetes.